Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.

Lene Kongsgaard NielsenTobias Wirenfeldt KlausenMary JardenHenrik FrederiksenAnnette Juul VangstedTrung DoIda Bruun KristensenUlf Christian FrølundChristen Lykkegaard AndersenNiels AbildgaardHenrik Gregersen

Published in: European journal of haematology (2018)

Despite the premature study termination, our data demonstrate impaired HRQoL when clarithromycin was added to the VCD regimen. We found clear underreporting of toxicities by clinicians. ClinicalTrials.gov number NCT02573935.

Keyphrases

multiple myeloma
helicobacter pylori
newly diagnosed
end stage renal disease
low dose
high dose
ejection fraction
helicobacter pylori infection
chronic kidney disease
palliative care
electronic health record
machine learning
big data
deep learning